A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.

In this study, therapy with ATI-2042 was associated with a mild trend for the number of episodes to increase with doses up to 600 mg bid, but this was offset by a substantial shortening of mean AF episode duration at all doses that reached statistical significance.

also in 257 other papers

The PR interval showed a trend towards decreasing: reductions from baseline were 16.6 ± 23.9% at 200 mg bid, 11.4 ± 22.6% at 400 mg bid, 27.0 ± 32.1% at 600 mg bid, 35.1 ± 30.9% at 800 mg bid, and 30.7 ± 24.3% at washout.

also in 53,322 other papers

There was a trend towards correlation between AFB, AF episodes or averaged sinus rhythm duration, and trough levels of ATI-2042, but this did not reach statistical significance.

also in 111,027 other papers